Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 GI Tolerability with Diet and Supplements
NCT03198767Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of licogliflozin in obesity (7 arms), sponsored by Novartis. Primary endpoint: Number of Episodes of Diarrhea at Day 3. Started Jun 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03198767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198767.